

## Report from Annual General Meeting of Vitrolife AB (publ)

At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

- Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
- Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
- Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1 350 000 (1 200 000) to the Chairman of the Board, SEK 450 000 (400 000) to each of the other members of the Board, SEK 160 000 (150 000) to the Chairman of the Audit Committee and SEK 80 000 (75 000) to each of the other members of the Audit Committee.
- The Election Committee proposes re-election of the auditor Deloitte AB and with unchanged remuneration principles.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
- Resolution to entering a share swap agreement in order to secure delivery of shares to participants in LTIP 2025 and the potential financial impacts of LTIP 2025.

Gothenburg, April 29, 2025  
VITROLIFE AB (publ)  
The Board

The information was submitted for publication, through the agency of the contact persons set out above, at 29-04-2025 16:56 CET.

**Contact:**

Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolifegroup.com](http://www.vitrolifegroup.com).